Dose intensity of oxaliplatin in 5-fluorouracil and leucovorin regimens in pretreated metastatic colorectal cancer.

被引：0
|
作者：
Jeong, KJ
Oh, JM
Choi, SK
Oh, D
机构：
[1] Sookmyung Womens Univ, Seoul, South Korea
[2] Pochon CHA Univ, Kyonggi Do, South Korea
来源：
PHARMACOTHERAPY | 2002年 / 22卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
203
引用
收藏
页码：1356 / 1356
页数：1
相关论文
共 50 条
  • [1] Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer
    Maindrault-Goebel, F
    de Gramont, A
    Louvet, C
    André, T
    Carola, E
    Gilles, V
    Lotz, JP
    Tournigand, C
    Mabro, M
    Molitor, JL
    Artru, P
    Izrael, V
    Krulik, M
    [J]. ANNALS OF ONCOLOGY, 2000, 11 (11) : 1477 - 1483
  • [2] Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer
    deGramont, A
    Vignoud, J
    Tournigand, C
    Louvet, C
    Andre, T
    Varette, C
    Raymond, E
    Moreau, S
    LeBail, N
    Krulik, M
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (02) : 214 - 219
  • [3] Oxaliplatin, leucovorin and fluorouracil in pretreated patients with advanced colorectal cancer.
    deGramont, A
    Tournigand, C
    Louvet, C
    Andre, T
    Molitor, JL
    Raymond, E
    Moreau, S
    Vignoud, J
    LeBail, N
    Krulik, M
    [J]. REVUE DE MEDECINE INTERNE, 1997, 18 (10): : 769 - 775
  • [4] Oxaliplatin reintroduction in patients pretreated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer (MCRC).
    Maindrault-Goebel, F
    Louvet, C
    André, T
    Carola, E
    Gilles, V
    Garcia, M
    Lotz, JP
    Izrael, V
    Krulik, M
    de Gramont, A
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 50 - 50
  • [5] Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer
    Chiara, S
    Nobile, MT
    Gozza, A
    Taveggia, P
    Heouaine, A
    Pastrone, I
    Percivale, PL
    Lionetto, R
    Sanguineti, O
    Rosso, R
    [J]. ANTICANCER RESEARCH, 2004, 24 (01) : 355 - 360
  • [6] Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer
    McWilliams, Robert R.
    Goetz, Matthew P.
    Morlan, Bruce W.
    Salim, Muhammad
    Rowland, Kendrith M.
    Krook, James E.
    Ames, Matthew M.
    Erlichman, Charles
    [J]. CLINICAL COLORECTAL CANCER, 2007, 6 (07) : 516 - 521
  • [7] Third line oxaliplatin with leucovorin (LV) and continuous infusion 5-fluorouracil (5FU) in metastatic colorectal cancer.
    Abón, G
    Muñoz, A
    Rubio, I
    Mañé, JM
    Ferreiro, J
    Fernández, R
    Fuente, N
    López-Argumedo, G
    Barceló, R
    Vivanco, GL
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 48 - 49
  • [8] Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer
    Arkenau, Hendrik-Tobias
    Graeven, Ullrich
    Kubicka, Stephan
    Grothey, Axel
    Englisch-Fritz, Christina
    Kretzschmar, Albrecht
    Greil, Richard
    Freier, Werner
    Seufferlein, Thomas
    Hinke, Axel
    Schmoll, Hans-Joachim
    Schmiegel, Wolff
    Porschen, Rainer
    [J]. CLINICAL COLORECTAL CANCER, 2008, 7 (01) : 60 - 64
  • [9] Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen
    André, T
    Louvet, C
    Raymond, E
    Tournigand, C
    de Gramont, A
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (11) : 1251 - 1253
  • [10] Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC)
    Kouroussis, C
    Souglakos, J
    Mavroudis, D
    Papadouris, S
    Kakolyris, S
    Agelaki, S
    Kalbakis, K
    Panopoulos, C
    Vardakis, N
    Sarra, E
    Georgoulias, V
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (06): : 627 - 631
12345